Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL

Medical oncology care amidst the COVID-19 pandemic at the National University Hospital in the Philippines

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma

Treating patients with multiple myeloma in the real world

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML

New CAR T therapy for relapsed and refractory ALL

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera